We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksLSAI.L Regulatory News (LSAI)

  • There is currently no data for LSAI

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Proposed Fundraise of up to £3.85m - Notice of GM

4 May 2021 07:00

RNS Number : 3297X
Location Sciences Group PLC
04 May 2021
 

 

4 May 2021

 

This announcement contains inside information for the purposes of Regulation 11 of the Market Abuse (Amendment) (EU Exit) Regulations 2019/310. With the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.

 

 

Location Sciences Group PLC

("Location Sciences" or the "Company" or the "Group")

 

Conditional Placing and Subscription of 1,750,000,000 Ordinary Shares at 0.2 pence per share,

Conditional Broker Option of up to 175,000,000 Ordinary Shares at 0.2 pence per share,

Approval of Waiver of Rule 9 of the City Code on Takeovers and Mergers

Proposed Board Changes

and

Notice of General Meeting

 

 

Location Sciences (AIM: LSAI), the leading location data insight and verification company, announces that it has conditionally raised up to £3.85 million before expenses for the Company through the issue of new Ordinary Shares.

 

 

Key features

 

· Placing and Subscription to raise £3.5 million before expenses at the Placing Price of 0.2 pence per Ordinary Share.

 

· Broker Option to raise up to £350,000 (before expenses) to meet any additional demand from Shareholders for Ordinary Shares - Broker Option closes to Shareholders at 8.00 a.m. on 5 May 2021.

 

· Issue of warrants over Ordinary Shares in relation to the Placing and Subscription.

 

· Participation in the Placing by a broad range of new investors.

 

· Placing and Subscription to provide funding to Location Sciences to continue development and commercialisation of the Company's products and services and for general working capital purposes.

 

· New Non-Executive Chairman and Non-Executive Director to be appointed at Admission in place of the current Non-Executive Chairman and Non-Executive Director. A further new Non-Executive Director to be appointed in due course.

 

· New strategic shareholders, including Mahmud Kamani, Founder & Group Executive Chairman at Boohoo Group plc and Richard Hughes, founder at Zeus Capital.

 

· Mahmud Kamani and Richard Hughes have together introduced Simon Wilkinson, a highly experienced software executive and entrepreneur, as a proposed investor and proposed Non-Executive Chairman of the Company.

 

· Transaction subject to Shareholder approval.

 

Background to the Transaction

On 11 February 2021, the Company announced that, in part as a consequence of COVID-19, the Company and in particular, Verify, would continue to face a number of trading challenges. This is despite the current relative strength of the Company's working capital position. Included within this announcement, the Board advised Shareholders that they were exploring a number of options for the Company and its businesses and further announcements would be made as and when appropriate.

Since that announcement, and following numerous discussions, both internally and with third parties, surrounding the business review, the Board has concluded that given the market outlook for each of the Company's business units, it is essential that Location Sciences secures additional financial resources. The Directors believe this will give the Company more time and greater flexibility to deliver value to the Shareholders from the Company's two core business units, namely location verification and data and insights.

Pleasingly the Board, with the assistance of Turner Pope, has secured the investment commitment and support, conditional upon Shareholder approval, from inter alia, Mahmud Kamani, Founder & Group Executive Chairman at Boohoo Group plc and Richard Hughes, founder at Zeus Capital.

The addition of these new supportive shareholders and the experience and relationships of the Proposed Directors, together with the additional resources from the Placing and Subscription, would, in the Board's opinion, considerably enhance the opportunities available to the Company.

Broker Option

Any Shareholder wishing to apply for any Broker Option Shares, unless they are themselves a FCA authorised market counterparty, will need to communicate their interest in Broker Option Shares to Turner Pope via a FCA authorised market counterparty such as a stockbroker or other firm authorised by the FCA by 8.00 a.m. on 5 May 2021.

 

 

Mark Slade, Chief Executive Officer of Location Sciences, commented: "Following a lengthy strategic review of the business, the Board is pleased to announce this fundraising, which has been secured despite the challenging trading environment being experienced by the Company. We are extremely cognisant of the discount to the current share price. However, the Board believes the fundraise is in the long-term interests of the business and its Shareholders. We look forward to welcoming the new strategic investors and Board members, who bring with them a wealth of relationships and opportunities which we hope will be of benefit to Location Sciences."

 

 

A copy of this announcement is available on the Company's website https://www.locationsciencesgroup.ai/investor-relations/documents-circulars/

 

 

For further information please contact:

 

Location Sciences Group PLC via Milk & Honey PR

Mark Slade, Chief Executive Officer

David Rae, CFO and Commercial Director

 

Allenby Capital Limited (Nominated Adviser) Tel: +44 (0)20 3328 5656

David Hart

David Worlidge

 

Turner Pope Investments (TPI) Ltd (Placing Agent) Tel: +44 (0)20 3657 0050

James Pope

Andy Thacker

 

Peterhouse Capital (Broker) Tel: +44 (0) 20 7220 9791

Charles Goodfellow

Eran Zucker

 

Milk & Honey PR Tel: +44 (0)20 3637 7310

Kirsty Leighton

Jessica Ballinger

 

 

 

Conditional Placing and Subscription of 1,750,000,000 Ordinary Shares at 0.2 pence per share,

Conditional Broker Option of up to 175,000,000 Ordinary Shares at 0.2 pence per share,

Approval of Waiver of Rule 9 of the City Code on Takeovers and Mergers

Proposed Board Changes

and

Notice of General Meeting

 

 

1. INTRODUCTION

The Company announces that it has conditionally raised up to £3.85 million before expenses for the Company through the issue of new Ordinary Shares.

The Transaction is, amongst other things, conditional upon each of the Resolutions being passed at the forthcoming General Meeting and includes:

- a Placing and Subscription with certain institutional and other investors, to raise £3.5 million before expenses through the issue of 1,750,000,000 Ordinary Shares (together, the "Placing Shares" and the "Subscription Shares") at the Placing Price of 0.2 pence per Ordinary Share. The Placing Price is at a discount of approximately 64 per cent. to the closing middle market price of 0.56 pence per Existing Ordinary Share on 30 April 2021, being the latest practicable date prior to the publication of this announcement;

 

- a Broker Option to raise up to £350,000 (before expenses) pursuant to which Turner Pope may conditionally allocate up to 175,000,000 Ordinary Shares (in addition to the Placing Shares) (the "Broker Option Shares") at the Placing Price in order to give the flexibility to meet any additional demand from Shareholders for Ordinary Shares arising during the period from the announcement of the Transaction up to 8.00 a.m. on 5 May 2021;

 

- the issuance of the Fees Shares, whereby: (i) 17,500,000 Ordinary Shares are to be issued at the Placing Price in respect of the first year of fees due to Turner Pope for the provision of its broking services to the Company; (ii) 120,500,000 Ordinary Shares are to be issued at the Placing Price in settlement of fees and commission due to Turner Pope pursuant to the Placing; and (iii) 85,000,000 Ordinary Shares are to be issued at the Placing Price in settlement of the first and second year's fees of the Proposed Directors;

 

- the issuance of Promoter Warrants, whereby non-transferable warrants to subscribe for up to 1,500,000,000 Ordinary Shares (equivalent to approximately 85.7 per cent. of the Placing Shares and Subscription Shares issued), exercisable at the Placing Price for five years from Admission, are to be issued to certain members of the Concert Party in consideration of those persons assembling and co-ordinating the Concert Party's investment in the Company and facilitating the proposed appointment of Simon Wilkinson as Non-Executive Chairman;

 

- the issuance of Cornerstone Investor Warrants, whereby non-transferable warrants to subscribe for up to 250,000,000 Ordinary Shares (equivalent to approximately 14.3 per cent. of the Placing Shares and Subscription Shares issued), exercisable at the Placing Price for five years from Admission, are to be issued to the Cornerstone Investors;

 

- the issuance of Director Warrants, whereby non-transferable warrants to subscribe for, in aggregate, 120,000,000 Ordinary Shares are issued to the Executive Directors and the Proposed Directors, (equivalent to approximately 6.9 per cent. of the Placing Shares and Subscription Shares issued), exercisable at the Placing Price for five years from Admission, provided that the Ordinary Shares have traded at a Volume Weighted Average Price (VWAP) at or above a 50 per cent. premium to the Placing Price for 20 consecutive Business Days, or on a change of control of the Company. The Director Warrants are to be issued to the Executive Directors and the Proposed Directors as part of their incentive package;

 

- the issuance of Broker Warrants, whereby transferable warrants to subscribe for up to 100,000,000 Ordinary Shares (equivalent to 5.7 per cent. of the Placing Shares and Subscription Shares issued), exercisable at the Placing Price for five years from Admission, are issued to JIM Nominees Limited (as nominee on behalf of Turner Pope) as part of the consideration payable to Turner Pope for its services as placing agent to the Transaction. Turner Pope has agreed to transfer, in aggregate, 41,250,000 Broker Warrants to Dr Nigel Burton and the Executive Directors upon Admission;

 

- proposed changes to the Board (namely the appointment of the Proposed Directors on the terms summarised in paragraph 10 below); and

 

- the Rule 9 Waiver.

 

The proceeds receivable by the Company from the Transaction on Admission amount to £3.5 million (before expenses) and approximately £3.35 million (net of expenses) (assuming that no Broker Option Shares are issued). If the Broker Option Shares are issued in full, the proceeds receivable by the Company from the Transaction amount to £3.85 million (before expenses) and approximately £3.7 million (net of expenses).

Immediately following Admission, the Concert Party will hold, in aggregate, 1,035,000,000 Ordinary Shares, representing approximately 41.1 per cent. of the Enlarged Issued Share Capital. If the Promoter Warrants and the Director Warrants held by members of the Concert Party following Admission are exercised, a further 25,000,000 Fees Shares are issued to Simon Wilkinson, the Broker Option is not exercised, no other options or warrants are exercised and no other Ordinary Shares are issued, the Concert Party would hold 2,590,000,000 Ordinary Shares representing 63.6 per cent. of the so enlarged ordinary share capital. If the Broker Option, the Promoter Warrants, the Cornerstone Investor Warrants, the Broker Warrants, and the Director Warrants are exercised in full and a further 25,000,000 Fees Shares are issued to Simon Wilkinson (and assuming no other issuance, including such as that which may arise from the exercise of other options which may be granted to other employees in future), the Concert Party would hold 2,590,000,000 Ordinary Shares representing 55.0 per cent. of the so enlarged ordinary share capital. In the unlikely event that the existing employee share options over 23,466,666 Ordinary Shares, which have an exercise price of 2.25 pence per share, are also exercised, then the Concert Party's holding would reduce to 54.8 per cent. of the so enlarged ordinary share capital.

Under Rule 9 of the Takeover Code, on Admission, the Concert Party would normally be obliged to make a general offer to all Shareholders (other than the Concert Party) to acquire all the Ordinary Shares not owned by the Concert Party. The Panel has agreed to waive these obligations subject to the approval (on a poll) of the Independent Shareholders of Resolution 1 to be proposed at the General Meeting. The Placing is therefore subject to the approval of that resolution by the Independent Shareholders. Your attention is drawn to paragraph 6 below which contains further information on the Takeover Code and the waiver of Rule 9 of the Takeover Code.

A General Meeting has been convened for 10.00 a.m. on 21 May 2021 and will be held at the offices of Turner Pope at 8 Frederick's Place, London, EC2R 8AB.

At present, as a result of the COVID-19 pandemic, there continue to be restrictions on gatherings of people indoors. The Company will therefore arrange to hold the General Meeting as a closed meeting, with the minimum attendance required to form a quorum under the Company's articles of association. These Shareholders will each be directors, officers or employees of the Company. Shareholders will not be permitted to attend the General Meeting in person but can be represented by the Chairman of the General Meeting acting as their proxy.

Given the uncertainty around whether Shareholders will be able to attend the General Meeting, all Shareholders are recommended to complete and return their Form of Proxy to arrive no later than 10.00 a.m. on 19 May 2021 appointing the Chairman of the General Meeting, as their proxy. This will ensure that Shareholders' votes will be counted even if attendance at the General Meeting is restricted or Shareholders are unable to attend in person. Alternatively, Shareholders may appoint their proxy electronically via the Registrar's website at www.investorcentre.co.uk/eproxy. Shareholders will need their Control Number, SRN & PIN which can be found on their Form of Proxy. CREST members can also vote by utilising the CREST electronic proxy appointment service in accordance with the procedures set out in the Notice. Further instructions for voting can be found in paragraph 14 below.

If approved, the Resolutions would provide the Directors with the authority to allot the Placing Shares, the Subscription Shares, the Broker Option Shares, the Fees Shares, and to satisfy in full the prospective issuance of Ordinary Shares arising from the exercise of the Promoter Warrants, the Cornerstone Investor Warrants, the Broker Warrants and the Director Warrants, and to dis-apply statutory pre-emption rights in respect thereof. They also include Resolutions to appoint the Proposed Directors, as set out in paragraph 10 below.

The Transaction is conditional, inter alia, upon: (i) the passing by Shareholders of all of the Resolutions at the General Meeting; (ii) the Placing Agreement not having been terminated and becoming unconditional in all respects save for Admission; and (iii) Admission having become effective by no later than 8.00 a.m. on 25 May 2021 (or such time and date as the Company, Allenby Capital and Turner Pope may agree, being no later than 8.00 a.m. on 22 June 2021). Subject to all relevant conditions being satisfied (or, if applicable, waived), it is expected that Admission will occur on or around 25 May 2021.

For the purposes of the Transaction, the Executive Directors are not considered to be independent in light of their involvement in the Transaction. As a result, they do not accept responsibility for the views of the Board on the Transaction and are not participating in the recommendation to Shareholders.

Shareholders should be aware that if the Resolutions are not approved at the General Meeting, the Transaction will not proceed in any respect. Shareholders are urged to vote in favour of the Resolutions, which the Independent Directors consider to be in the best interests of the Shareholders as a whole.

2. BACKGROUND TO THE TRANSACTION

On 11 February 2021, the Company announced that, in part as a consequence of COVID-19, the Company and in particular, Verify, would continue to face a number of trading challenges. This is despite the current relative strength of the Company's working capital position. Included within this announcement, the Board advised Shareholders that they were exploring a number of options for the Company and its businesses and further announcements would be made as and when appropriate.

Since that announcement, and following numerous discussions, both internally and with third parties, surrounding the business review, the Board has concluded that given the market outlook for each of the Company's business units, it is essential that Location Sciences secures additional financial resources. The Directors believe this will give the Company more time and greater flexibility to deliver value to the Shareholders from the Company's two core business units, namely location verification and data and insights.

Pleasingly the Board, with the assistance of Turner Pope, has secured the investment commitment and support, conditional upon each of the Resolutions being passed at the forthcoming General Meeting, from inter alia, Mahmud Kamani, Founder & Group Executive Chairman at Boohoo Group plc and Richard Hughes, founder at Zeus Capital, each of whom form part of the Concert Party. Mahmud Kamani and Richard Hughes have together introduced Simon Wilkinson as a proposed investor and proposed Non-Executive Chairman of the Company and as a member of the Concert Party.

The addition of these new supportive shareholders and the experience and relationships of the Proposed Directors, together with the additional resources from the Placing and Subscription, would, in the Board's opinion, considerably enhance the opportunities available to the Company.

3. COMPANY OVERVIEW

About the Company

Location Sciences is a global location verification provider to the digital advertising industry, and works in partnership with advertisers, media agencies and suppliers to reduce ad wastage and improve the effectiveness of location-based advertising campaigns.

Location Sciences has developed Verify and GeoProtect, the world's first independent location verification products, to tackle the global location ad fraud problem. Utilising sophisticated machine learning and pattern recognition technologies, Verify and GeoProtect detect location ad fraud and highlight location data inaccuracy with the aim of bringing back integrity, transparency and trust to the marketplace.

Location Sciences is also a specialised footfall insights company in the UK, combining cutting-edge GDPR compliant location data collection with proprietary machine learning analytics to create new value and insights from location information.

Recent trading

Trading performance for the year to 31 December 2020

For the year to 31 December 2020, revenue reduced to £1,080,742 (2019: £1,206,254) representing a decrease in revenues of approximately 10 per cent. year-on-year. Location data and insights delivered £762,170 of revenue (2019: £710,700) with Verify contributing £318,572 (2019: £495,554).

The Group received £30,119 of grant income, including £20,119 of furlough income from the UK's job retention scheme in 2020 (2019: £25,280). There is no grant income expected in the foreseeable future.

In response to the COVID-19 pandemic, the Board made swift cost reductions to mitigate the impact of the downturn in revenues. These included salary reductions for the Board and senior members of the team, a hiring freeze, closure of the London office and staff being furloughed. In addition, with the exception of product development, all operational expenses were reduced to the minimal viable levels from April 2020 following the downturn in the location-based advertising industry caused by the restrictions imposed by governments globally.

These actions reduced the administrative costs for continuing operations excluding depreciation and amortisation to £1,535,906 (2019: £2,545,767) a reduction of 40 per cent. compared to the prior year.

The business delivered a loss before exceptional items, amortisation and depreciation of £783,242 (2019: £1,712,986), an operating loss of £1,400,019 (2019: £2,271,242) and a loss after taxation of £1,239,268 (2019: £2,116,812).

Loss per Ordinary Share from continuing operations decreased from 0.61 pence in 2019 to 0.24 pence in 2020.

Impact of COVID-19

Verify revenues have continued to be adversely impacted by the significantly reduced advertising spend caused by the pandemic. The anticipated uplift in Verify revenues during the fourth quarter of 2020 did not materialise and there has been no improvement in the first part of 2021 due to the ongoing restrictions being imposed by governments globally.

As reported during 2020, it has been a challenging time for location-based advertising within sectors that rely on people's movement, such as retail and Quick Service Restaurants.

The outlook for location-based advertising is poor due to the overall impact of the pandemic on the location-based advertising industry. In the Board's experience, mainstream media agencies are now focused on media delivery rather than adopting new technologies, especially those which risk limiting delivery scale such as Verify.

Location Verification

In the first two months of 2020, the Board was buoyed by the momentum building around Verify which included being added to the Group M technology partner list, trials with Starbucks, Unilever and Horizon Media Inc., as well as deals with Phillip Morris International and Dentsu Aegis.

Unfortunately, this momentum was halted by COVID-19. Reduced media spending on location-based advertising resulted in a significantly reduced number of campaigns for location verification. More significantly, a new layer of verification was something media agencies would not promote given their need to spend and deliver revenues. In the UK, preferred partner relationships between location suppliers and their media agencies amplified this challenge. The recent dispute which the Company has had with Blis is evidence of how these relationships can override the Verify platform findings.

It is the management team's belief that the Verify platform needs a direct sales channel into brands and for the budget holders to see the problem our products are solving. Although this is a deeply opaque and unregulated part of digital advertising market, the Directors believe more work is needed to educate brands on the inefficiencies caused by poor data and the data quality and fraud issues omnipresent on the location-based advertising supply chain.

Following the announcement of the business review, the management team is exploring options for the Company's location verification products that could support the brand direct channel strategy. It is the management team's belief that with the right partners this can still be a successful SAAS offering.

The Directors are confident that the Company's products solve a significant problem in the ad-tech ecosystem. However, finding the right partners who are committed to promoting transparency will be a key next step. The recent changes in the ad-tech ecosystem such as the loss of cookies and the move to real time context are also creating some macro tail winds and scope for optimism.

Data and Insights

The Data and Insights business has fared better despite a drop in location events due to lack of movement from various lockdowns. Customers such as CACI, JC Decaux and the NHS have relied on the Company's data to show movement trends during the different phases of the COVID-19 pandemic.

The supply of data which feeds the Data and Insights business is being affected by the privacy changes introduced by the main operating systems. However, the Location Sciences management team continue to explore new supply relationships in order to maintain the data at a level suitable for the level of insights the Company delivers.

The Board is excited about the launch of the Company's new Insights products for the financial services industry, with the first such product launching on the Bloomberg Enterprise Access Point in the next few months.

The Data and Insights business also faces challenges, in particular with regards to location data supply, with Google and Apple having a significant influence on how location data is collected and processed. The Company has weathered the challenges of location data supply to date; however, these challenges have limited the growth of the Company's Data and Insights business as well as increased the costs to the Company. Consequently, this business unit is not yet break even and will require further investment to realise its full potential.

Outlook

There is still significant uncertainty ahead for Location Sciences. The management team is optimistic that as COVID-19 restrictions are relaxed the brakes on Location Sciences' business will be eased.

On 11 February 2021, the Company announced that, in part as a consequence of COVID-19, the Company and in particular, Verify, would continue to face a number of trading challenges. This is despite the current relative strength of the Company's working capital position. As made clear above, the key for Verify is to find the right partners who are committed to promoting transparency. In the Board's view, this is imperative to deliver the value of Verify to shareholders.

4. USE OF PROCEEDS

The Company intends to use the funds raised from the Transaction:

- to fund the commercialisation of Location Sciences' current products and services;

 

- to provide funds to further develop Location Sciences' product and service portfolio; and

 

- for general working capital purposes.

 

5. INFORMATION ON THE TRANSACTION

Details of the Placing

The Placing is conditional, inter alia, upon:

- all of the Resolutions being passed without amendment at the General Meeting;

 

- the Company allotting, subject only to Admission, the Placing Shares and the Broker Option Shares (if any) in accordance with the Placing Agreement;

 

- Admission becoming effective by no later than 8.00 a.m. on 25 May 2021 (or such other time and/or date, being no later than 8.00 a.m. on 22 June 2021, as Allenby Capital, Turner Pope and the Company may agree);

 

- the conditions in the Placing Agreement being satisfied or (if applicable) waived; and

 

- the Placing Agreement not having been terminated in accordance with its terms prior to Admission.

 

The Placing Shares will be credited as fully paid and will rank pari passu in all respects with the Ordinary Shares then in issue, including the right to receive all future distributions, declared, paid or made in respect of the Ordinary Shares from the date of Admission. The Placing Shares will represent approximately 69.0 per cent. of the Enlarged Issued Share Capital, if no Broker Option Shares are issued.

None of the Directors nor the Company give any warranty or undertaking that a subscription for VCT/EIS Shares: (i) is a qualifying holding for the purposes of Part 6 of the Income Tax Act 2007, or that such qualifying status will not be withdrawn; or (ii) would be regarded as "eligible shares" for the purposes of Part 5 of the Income Tax Act 2007, nor do they warrant or undertake that the Company will conduct its activities in a way that qualifies for or preserves its status or the status of any investment in New Ordinary Shares. Investors considering taking advantage of any of the reliefs available to VCTs or under EIS should seek their own professional advice in order that they may fully understand how the rules apply in their individual circumstances and what they are required to do in order to claim any reliefs (if available). As the rules governing VCT and/or EIS reliefs are complex and interrelated with other legislation, if any potential investors are in any doubt as to their tax position, require more detailed information than the general outline above, or are subject to tax in a jurisdiction other than the UK, they should consult own their professional advisers.

Application will be made for the Placing Shares, the Subscription Shares, the Broker Option Shares (if any) and the Fees Shares (excluding 42,500,000 Fees Shares in respect of the second year's fees of the Proposed Directors) to be admitted to trading on AIM following the approval of the Resolutions. Admission is expected to become effective by no later than 8.00 a.m. on 25 May 2021. Settlement of the Placing Shares, the Subscription Shares, the Broker Option Shares (if any) and the Fees Shares (excluding 42,500,000 Fees Shares in respect of the second year's fees of the Proposed Directors) is expected to take place within the CREST system in conjunction with Admission.

It is expected that CREST accounts of the Placees who hold their Ordinary Shares in CREST will be credited with their Placing Shares and/or Broker Option Shares on 25 May 2021. In the case of Placees holding Ordinary Shares in certificated form, it is expected that certificates will be dispatched during the week commencing 31 May 2021.

The Placing and the Subscription are not being underwritten and the Placing Shares, the Subscription Shares and the Broker Option Shares are not subject to clawback.

Subscription

The Subscription Shares will be issued at the Placing Price, raising £25,000 for the Company. One of the Executive Directors has subscribed directly with the Company for these shares, which are issued on the same terms and conditions as the Placing Shares.

Details of the Broker Option

The Company has granted the Broker Option to Turner Pope to enable the Company to raise additional funds in the event of there being additional demand under the Placing. The Broker Option enables Turner Pope to procure subscribers for up to 175,000,000 Broker Option Shares, at the Placing Price, which they may use to satisfy additional demand for Ordinary Shares. Turner Pope may exercise the Broker Option during the period from the time of this announcement (on more than one occasion if partially exercising) at any time up to 5.00 p.m. on 5 May 2021. The allotment and issue of the Broker Option Shares is subject to the Placing proceeding and all Resolutions having been passed, amongst other things.

Any issue of Broker Option Shares will be made on the same terms and conditions as the issue of the Placing Shares. The Broker Option Shares are not being offered to the public and are not being offered or sold in any jurisdiction where it would be unlawful to do so. Any Shareholder wishing to apply for any Broker Option Shares, unless they are themselves an FCA authorised market counterparty, will need to communicate their interest in Broker Option Shares to Turner Pope via a FCA authorised market counterparty such as a stockbroker or other firm authorised by the FCA by 8.00 a.m. on 5 May 2021. Turner Pope will have absolute discretion in the allocation of any Broker Option Shares following the communication of any such interest, and communication of an order to Turner Pope will not guarantee any person any allocation or participation. The Broker Option Shares, if and when issued, will be credited as fully paid and will rank pari passu in all respects with the Ordinary Shares then in issue, including the right to receive all future distributions, declared, paid or made in respect of the Ordinary Shares from the date of Admission. If the Broker Option is fully exercised, the Broker Option Shares arising will represent approximately 6.5 per cent. of the Enlarged Issued Share Capital as further increased by the full issuance of the Broker Option Shares.

Details of the Fees Shares

The Fees Shares comprise:

- 17,500,000 Ordinary Shares to be issued at the Placing Price in respect of £35,000 for the first year of fees, paid in advance, due to Turner Pope for the provision of its broking services to the Company following Admission, upon which it will be appointed as joint broker to the Company;

 

- 120,500,000 Ordinary Shares are to be issued at the Placing Price in settlement of fees and commission due to Turner Pope pursuant to the Placing; and

 

- 85,000,000 Ordinary Shares to be issued at the Placing Price in respect of the first and second year's fees of the Proposed Directors, paid in advance, as set out in paragraph 10 below.

 

The issue of the Fees Shares reflects the agreement of Turner Pope and the Proposed Directors to apply the amounts owed to them by the Company in paying up new Ordinary Shares. The Fees Shares (other than the 42,500,000 Fees Shares to be issued in respect of the second year's fees of the Proposed Directors) will be issued at Admission, credited as fully paid and will rank pari passu in all respects with the Ordinary Shares then in issue, including the right to receive all future distributions, declared, paid or made in respect of the Ordinary Shares from the date of Admission. The Fees Shares (excluding the 42,500,000 Fees Shares to be issued in respect of the second year's fees of the Proposed Directors) will represent approximately 7.2 per cent. of the Enlarged Issued Share Capital, if no Broker Option Shares are issued, or approximately 6.7 per cent. of the Enlarged Issued Share Capital as further increased if the Broker Option is exercised in full.

Details of the Promoter Warrants

Pursuant to the terms of the Promoter Warrant Instrument, the Company will, conditional upon Admission, grant warrants to subscribe for up to 1,500,000,000 Ordinary Shares, which represents 85.7 per cent. of the Placing Shares and the Subscription Shares, to Richard Hughes, Mahmud Kamani and Simon Wilkinson, who are members of the Concert Party. The exercise price of the Promoter Warrants shall be the Placing Price and the Promoter Warrants shall be capable of exercise for a period of five years from Admission. The Promoter Warrants will not be listed and will not be transferable. The Promoter Warrants will be allocated as set out below:

Name

Number of Ordinary Shares

subject to Promoter Warrants

 

Richard Hughes

500,000,000

Mahmud Kamani

500,000,000

Simon Wilkinson

500,000,000

TOTAL

1,500,000,000

Details of the Cornerstone Investor Warrants

Pursuant to the terms of the Cornerstone Investor Warrant Instrument, the Company will, conditional upon Admission, grant warrants to subscribe for up to 250,000,000 Ordinary Shares, which represents 14.3 per cent. of the Placing Shares and the Subscription Shares, to the Cornerstone Investors. The exercise price of the Cornerstone Investor Warrants shall be the Placing Price and the Cornerstone Investor Warrants shall be capable of exercise for a period of five years from Admission. The Cornerstone Investor Warrants will not be listed and will not be transferable. The Cornerstone Investor Warrants will be allocated as set out below:

Name

Number of Ordinary Sharessubject to Cornerstone Investor Warrants

Ben Turner

50,000,000

Donna Turner

75,000,000

James Pope

50,000,000

Maxine Pope

75,000,000

TOTAL

250,000,000

Details of the Broker Warrants

Pursuant to the terms of the Broker Warrant Instrument, the Company will, conditional upon Admission, grant warrants to subscribe for up to 100,000,000 Ordinary Shares, which represents 5.7 per cent. of the Placing Shares and the Subscription Shares, to JIM Nominees Limited (as nominee on behalf of Turner Pope). The exercise price of the Broker Warrants shall be the Placing Price and the Broker Warrants shall be capable of exercise for a period of five years from Admission. The Broker Warrants will not be listed, are transferable and any transfers must be registered with the Company. The Broker Warrants are exercisable by new holders on the same terms as they could be exercised by Turner Pope, subject to such new holders having been registered as holders of the Broker Warrants in accordance with the transfer terms of the Broker Warrant Instrument. Turner Pope has agreed to transfer, in aggregate, 41,250,000 Broker Warrants to Dr Nigel Burton and the Executive Directors upon Admission. Following such transfers, the Broker Warrants will be allocated as set out below:

Name

Number of Ordinary Sharessubject to Broker Warrants

JIM Nominees Limited (as nominee on behalf of Turner Pope)

58,750,000

Dr Nigel Burton

25,000,000

Mark Slade

10,000,000

David Rae

6,250,000

TOTAL

100,000,000

 

6. THE TAKEOVER CODE

The terms of the Transaction give rise to certain considerations under the Takeover Code. Brief details of the Panel, the Takeover Code and the protections they afford are given below.

Rule 9 of the Takeover Code

The Code is issued and administered by the Panel. The Company is a company to which the Code applies, and its Shareholders are entitled to the protections afforded by the Code. Under Rule 9 of the Code, any person who acquires an interest (as defined in the Code) in shares which, taken together with shares in which he is already interested and in which persons acting in concert with him are interested, carry 30 per cent. or more of the voting rights of a company which is subject to the Code, is normally required to make a general offer to all the remaining shareholders to acquire their shares.

If any person, together with persons acting in concert with him, is interested in shares which in the aggregate carry not less than 30 per cent. of the voting rights of a company but does not hold shares carrying more than 50 per cent. of such voting rights and such person, or any person acting in concert with him, acquires an interest in any other shares which increases the percentage of shares carrying voting rights in which he is interested, such person shall extend offers, on the basis set out in Rules 9.3, 9.4 and 9.5 of the Code, to the holders of any class of equity share capital whether voting or non-voting and also to the holders of any other class of transferable securities carrying voting rights. Offers for different classes of equity share capital must be comparable; the Panel should be consulted in advance in such cases.

An offer will not be required under Rule 9 of the Takeover Code where control of the offeree company is acquired as a result of a voluntary offer made in accordance with the Code to all the holders of voting equity share capital and other transferable securities carrying voting rights. Note 4 on Rule 9.1 of the Code further provides, among other things, that where any person who, together with persons acting in concert with him, holds over 50 per cent. of the voting rights of a company and acquires further shares, then they that person will not generally be required to make a general offer to the other shareholders to acquire the balance of their shares, although individual members of the concert party will not be able to increase their percentage interest in shares through or between a Rule 9 threshold, without Panel consent.

An offer under Rule 9 of the Code must be made in cash (or with a cash alternative) and at the highest price paid by the person required to make the offer, or any person acting in concert with him, for any interest in shares of the company during the 12 months prior to the announcement of the offer.

Rule 9 Waiver

Under Note 1 of the Notes on the Dispensations from Rule 9, the Panel may waive the requirement for a general offer to be made in accordance with Rule 9 if, amongst other things, the shareholders of a company who are independent of the person who would otherwise be required to make an offer, and any person acting in concert with him, pass an ordinary resolution on a poll at a general meeting or by way of a written resolution approving such a waiver.

The Company has applied to the Panel for the Rule 9 Waiver of the Code in order to permit the implementation of the Transaction without triggering an obligation on the part of the Concert Party, or any member of the Concert Party, to make a general offer to Shareholders. Subject to the approval of the Independent Shareholders of the Whitewash Resolution taken on a poll in General Meeting, the Panel has agreed to waive the obligations to make a offer under Rule 9 of the Code for the entire issued share capital of the Company that would otherwise arise as a result implementation of the Transaction. Accordingly, the Whitewash Resolution being proposed at the General Meeting will be taken by means of a poll of Independent Shareholders attending and voting at the General Meeting. Anybody who is not an Independent Shareholder cannot vote on the Whitewash Resolution. Any Shareholder, who is not an Independent Shareholder, has undertaken to the Company that they will not vote on the Whitewash Resolution.

The waiver to which the Panel has agreed under the Code will be invalidated if any purchases are made by any member of the Concert Party, or any person acting in concert with it, in the period between the date of this announcement and the General Meeting. No member of the Concert Party, nor any person acting in concert with it, has purchased Ordinary Shares in the 12 months preceding the date of this announcement.

Potential voting rights of the Concert Party

Persons acting in concert include persons who, pursuant to an agreement or understanding (whether formal or informal), co-operate to obtain or consolidate control of a company.

The Concert Party consists of Richard Hughes, Rebecca Hughes, Abigail Hughes, Mahmud Kamani, Samir Kamani, Umar Kamani, Adam Kamani, Petar Cvetkovic, Carol Kane, Daron Lee, John Lyttle, Shaun Mealey, Christian Stephenson and Simon Wilkinson, all of whom are presumed to be acting in concert under the Takeover Code. No member of the Concert Party holds any Existing Ordinary Shares.

The Concert Party will not be restricted from making an offer for the Company.

Maximum Controlling Position

The Concert Party has conditionally agreed to subscribe for, in aggregate,1,010,000,000 Ordinary Shares under the Placing. In addition, a member of the Concert Party is receiving 25,000,000 Fees Shares at Admission. Consequently, immediately following Admission, the Concert Party will hold, in aggregate, 1,035,000,000 Ordinary Shares, representing approximately 41.1 per cent. of the Enlarged Issued Share Capital. The Concert Party's acquisition of New Ordinary Shares would, without a waiver of the obligations under Rule 9 of the Takeover Code, oblige the Concert Party to make a general offer for the Company under Rule 9 of the Takeover Code.

As part of the Transaction, certain members of the Concert Party will be granted, in aggregate, 1,500,000,000 Promoter Warrants and 30,000,000 Director Warrants. Simon Wilkinson will also be issued with a further 25,000,000 Fees Shares in respect of his second year of service as Non-Executive Chairman. If the Promoter Warrants and the Director Warrants held by members of the Concert Party following Admission are exercised, a further 25,000,000 Fees Shares are issued to Simon Wilkinson, the Broker Option is not exercised, no other options or warrants are exercised and no other Ordinary Shares are issued, the Concert Party would hold 2,590,000,000 Ordinary Shares representing 63.6 per cent. of the so enlarged ordinary share capital.

If the Broker Option, the Promoter Warrants, the Cornerstone Investor Warrants, the Broker Warrants, and the Director Warrants are exercised in full and a further 25,000,000 Fees Shares are issued to Simon Wilkinson (and assuming no other issuance, including such as that which may arise from the exercise of other options which may be granted to other employees in future), the Concert Party would hold 2,590,000,000 Ordinary Shares representing 55.0 per cent. of the so enlarged ordinary share capital. In the unlikely event that the existing employee share options over 23,466,666 Ordinary Shares, which have an exercise price of 2.25 pence per share, are also exercised then the Concert Party's holding would reduce to 54.8 per cent. of the so enlarged ordinary share capital.

The exercise of any of the Promoter Warrants or Director Warrants held by members of the Concert Party and the issue of a further 25,0000,000 Fees Shares to Simon Wilkinson would, without a waiver of the obligations under Rule 9 of the Takeover Code, oblige the Concert Party to make a general offer to Shareholders under Rule 9 of the Takeover Code.

The following table sets out the Concert Party's shareholdings (i) on Admission; and (ii) following Admission (assuming that no Broker Option Shares are issued) in the event that all the Promoter Warrants and the Director Warrants held by members of the Concert Party are exercised, a further 25,000,000 Fees Shares are issued to Simon Wilkinson and no other options or warrants are exercised or further Ordinary Shares are issued.

 

Fees Shares

Placing

Shares

At Admission

Promoter Warrants

Director Warrants

Fees Shares

Maximum holding

 

No. Shares

No. Shares

No. Shares

%

No. Shares

No. Shares

No. Shares

No. Shares

%

Richard Hughes

-

200,000,000

200,000,000

7.94

500,000,000

-

-

700,000,000

17.19

Rebecca Hughes

-

50,000,000

50,000,000

1.99

-

-

-

50,000,000

1.23

Abigail Hughes

-

50,000,000

50,000,000

1.99

-

-

-

50,000,000

1.23

Mahmud Kamani

-

200,000,000

200,000,000

7.94

500,000,000

-

-

700,000,000

17.19

Samir Kamani

-

60,000,000

60,000,000

2.38

-

-

-

60,000,000

1.47

Umar Kamani

-

50,000,000

50,000,000

1.99

-

-

-

50,000,000

1.23

Adam Kamani

-

50,000,000

50,000,000

1.99

-

-

-

50,000,000

1.23

Petar Cvetkovic

-

25,000,000

25,000,000

0.99

-

-

-

25,000,000

0.68

Carol Kane

-

50,000,000

50,000,000

1.99

-

-

-

50,000,000

1.23

Daron Lee

-

125,000,000

125,000,000

4.96

-

-

-

125,000,000

3.07

John Lyttle

-

50,000,000

50,000,000

1.99

-

-

-

50,000,000

1.23

Shaun Mealey

-

25,000,000

25,000,000

0.99

-

-

-

25,000,000

0.68

Christian Stephenson

-

25,000,000

25,000,000

0.99

-

-

-

25,000,000

0.68

Simon Wilkinson

25,000,000

50,000,000

75,000,000

2.98

500,000,000

30,000,000

25,000,000

630,000,000

15.47

Total Concert Party

25,000,000

1,010,000,000

1,035,000,000

41.11

1,500,000,000

30,000,000

25,000,000

2,590,000,000

63.59

 

Waiver of Rule 9 of the Takeover Code

The Company applied to the Panel for a waiver of Rule 9 of the Takeover Code in order to permit members of the Concert Party to subscribe for in aggregate, 1,010,000,000 Ordinary Shares pursuant to the Placing, receive 50,000,000 Fees Shares and exercise the Promoter Warrants and Director Warrants held by the Concert Party without triggering an obligation on the part of the Concert Party to make a general offer for the Company. The Panel has agreed, subject to Resolution 1 to be proposed at the General Meeting being passed on a poll of Independent Shareholders, to waive the requirement for the Concert Party to make a general offer to all Shareholders where such an obligation would arise as a result of members of the Concert Party subscribing for Placing Shares pursuant to the Placing, receiving 50,000,000 Fees Shares and exercising the Promoter Warrants and Director Warrants held by the Concert Party.

In the event that the Rule 9 Waiver is granted by the Panel and the Concert Party exercises the Promoter Warrants and the Director Warrants held by members of the Concert Party and a further 25,000,000 Fees Shares are issued to Simon Wilkinson, the Concert Party may hold in excess of 50 per cent. of the so enlarged ordinary share capital. As such, the Concert Party would be entitled to further increase its holding or voting rights without incurring any further obligations under Rule 9 to make a mandatory offer, although individual members of the Concert Party will not be able to increase their percentage shareholding through or between a Rule 9 threshold without Panel consent.

If the Resolutions are approved at the General Meeting, the Concert Party will not be restricted from making an offer for the Company unless the Concert Party either makes a statement that it does not intend to make an offer or enters into an agreement with the Company not to make an offer. No such statement has been made or agreement entered into as at the date of this announcement.

Intentions of the Concert Party

Following completion of the Transaction, the Company's business will be continued in the same manner as it is at present. The Concert Party has confirmed that it has no current intention to change the Company's plans with respect to:

- the Company's existing business (including the Company's intentions for its research and development functions);

 

- the continued employment of the employees and management of the Company, including any material change in conditions of employment or in the balance of the skills and functions of the employees and management;

 

- its strategic plans for the Company, or their likely repercussions on employment or the locations of the Company's places of business, including on the location of the Company's headquarters and the headquarters' functions;

 

- employer contributions into any pension scheme(s), the accrual of benefits for existing members, or the admission of new members; or

 

- the redeployment of the fixed assets of the Company.

 

Relationship agreement

Given the size of the Concert Party's aggregate shareholding in the Company, the Company, Allenby Capital and each member of the Concert Party have entered into a relationship agreement to regulate the relationship between the Company and the Concert Party following Admission.

7. PLACING AGREEMENT

The Company has entered into the Placing Agreement with each of Allenby Capital and Turner Pope, pursuant to which Allenby Capital has agreed to act as nominated adviser and financial adviser in connection with the Transaction and Turner Pope has agreed (as the Company's placing agent) to use reasonable endeavours to procure placees for the Placing Shares at the Placing Price. The Company has also granted the Broker Option to Turner Pope, although Turner Pope is not obliged to use reasonable endeavours to procure placees for Broker Option Shares. The Placing Price represents a discount of approximately 64 per cent. to the closing mid-market price of 0.56 pence per Ordinary Share on 30 April 2021, being the latest practicable date prior to the publication of this announcement.

The Placing Agreement contains customary warranties given by the Company to Allenby Capital and Turner Pope as to matters relating to the Company and its business and a customary indemnity given by the Company to Allenby Capital and Turner Pope in respect of liabilities arising out of or in connection with the Transaction. Each of Allenby Capital and Turner Pope is entitled to terminate the Placing Agreement in certain circumstances prior to Admission, including circumstances where any of the warranties are found not to be true or accurate or to be misleading in any respect or on the occurrence of certain force majeure events.

The Placing Shares are not being offered to the public and are not being offered or sold in any jurisdiction where it would be unlawful to do so.

8. DIRECTORS' AND PROPOSED DIRECTORS' PARTICIPATION IN THE PLACING AND SUBSCRIPTION AND THEIR RESULTING INTERESTS IN THE COMPANY

The Executive Directors and Proposed Directors propose to subscribe for an aggregate of 120,000,000 Placing Shares and 12,500,000 Subscription Shares, representing approximately 7.6 per cent. of the Placing Shares and Subscription Shares. Immediately following Admission (assuming the issue of 42,500,000 Fees Shares but that no Broker Option Shares are issued), the Executive Directors and Proposed Directors will together hold an aggregate of 182,371,111 Ordinary Shares, representing 7.2 per cent. of the Enlarged Issued Share Capital, as set out in the table below. This figure decreases to 6.8 per cent. of the Enlarged Issued Share Capital as further increased if the Broker Option is exercised in full and excluding the 42,500,000 Fees Shares in respect of the second year's fees of the Proposed Directors.

Director

Number of Existing Ordinary Shares held

Number ofPlacing Shares subscribed for

Number of Subscription Shares subscribed for

Number ofFees Sharesto be issued at Admission

 

Resultingnumber of Ordinary Sharesheld immediately following Admission1

Resultingholding as a percentage of the Enlarged Issued Share Capital

Executive Directors

Mark Slade

6,204,444

20,000,000

-

-

26,204,444

1.0%

David Rae

1,166,667

-

12,500,000

-

13,666,667

0.5%

Proposed Directors

Simon Wilkinson

-

50,000,000

-

25,000,000

75,000,000

3.0%

Dr Nigel Burton

-

50,000,000

-

17,500,000

67,500,000

2.7%

TOTAL

7,371,111

120,000,000

12,500,000

42,500,00

182,371,111

7.2%

 

Note: The interests above assume no Broker Option Shares are issued and exclude the 22,888,889 unexercised but out-of-the-money options over Ordinary Shares held at the date of this announcement by the Executive Directors, as disclosed in the Company's 2020 Annual Report. It is expected that following Admission these options will be surrendered and that new options will be granted to the Executive Directors. If any new options are granted, details will be notified to Shareholders via a Regulatory Information Service.

9. RELATED PARTY TRANSACTIONS

The Directors' aggregate participation in the Placing and Subscription (as set out in paragraph 8 above) and their aggregate entitlement to Broker Warrants and Director Warrants (as set out in paragraphs 10 and 11 below) are deemed to constitute a related party transaction pursuant to Rule 13 and Rule 16 of the AIM Rules.

The Independent Directors, consider, having consulted with Allenby Capital, the Company's nominated adviser, that the terms of the Directors' aggregate participation in the Placing and Subscription and their aggregate entitlement to Broker Warrants and Director Warrants are fair and reasonable insofar as the Shareholders are concerned.

10. PROPOSED BOARD CHANGES

Conditional upon the approval of the Resolutions at the General Meeting and Admission, and subject always to the satisfactory discharge by Allenby Capital of its obligations under the AIM Rules for Nominated Advisers in respect of the board changes, it is intended that Simon Wilkinson will join the Board as Non-Executive Chairman and Dr Nigel Burton will join the Board as a Non-Executive Director, in each case at Admission. It is also intended that the current Non-Executive Chairman, Kelvin Harrison, and Non-Executive Director, Benjamin Chilcott, will step down from the Board at Admission.

On their appointment to the Board, it is proposed that the Company's Audit, Remuneration and Nomination Committees will be chaired by Dr Nigel Burton and Simon Wilkinson will be a member of all committees. Dr Nigel Burton will also assume the responsibilities of Senior Non-Executive Director.

Simon Wilkinson

Simon Wilkinson is a highly experienced software executive and entrepreneur, having been involved with a number of public and private companies over his career. He was most recently CEO then Chairman of Mobica, a world-leading, award-winning software services company offering bespoke development, QA and consultancy. He was previously Chief Executive Officer of Myriad Group AG, which was listed in Zurich, and founder and Chief Executive Officer of Magic4 Ltd, a mobile messaging software market leader, backed by 3i, Philips Ventures and Motorola Ventures, sold to Openwave Systems for $83 million in August 2004.

Dr Nigel Burton

Following over 14 years as an investment banker at leading City institutions including UBS Warburg and Deutsche Bank, including as the Managing Director responsible for the energy and utilities industries, Nigel spent 15 years as Chief Financial Officer or Chief Executive Officer of a number of private and public companies. Nigel is currently a Non-Executive Director of main listed, BlackRock Throgmorton Investment Trust plc, as well as AIM quoted companies, DeepVerge plc, eEnergy Group plc, Mobile Streams plc and Microsaic Systems plc.

Proposed remuneration and terms for the Proposed Directors

Proposed Director

Position

Appointment term

Annual Remuneration

Number of Fees Shares to be issued on Admission for first year of service

Number of new Ordinary Shares to be issued for second year of service

Number of Director Warrants to be issued (see paragraph 11 below)

Number of Broker Warrants to be issued (see paragraph 11 below)

Number of Promoter Warrants to be issued (see paragraph 11 below)

Simon Wilkinson

Non-Executive Chairman

Two years, subject to three months' notice*

£50,000

25,000,000

25,000,000

30,000,000

-

500,000,000

Dr Nigel Burton

Non-Executive Director, Chairman of the Audit Committee, Chairman of the Remuneration Committee and Chairman of the Nomination Committee

Two years, subject to three months' notice*

£35,000

17,500,000

17,500,000

30,000,000

25,000,000

-

* Notice cannot be given by the Proposed Directors during the first two years of their appointment except to the end of the period to which their fees have been paid in advance.

Summary details of the letters of appointment to be entered into between the Company and each of the Proposed Directors prior to Admission are set out below:

To make the most effective use of the proceeds, each of the Proposed Directors has agreed that for each of the first two years of their appointment, the relevant fee will be paid annually in advance and the payment owed by the Company to each of the Proposed Directors will be applied by them in paying up such number of Ordinary Shares as equals the annual remuneration set out in the table above divided by the Placing Price ("Director Fees Shares"), with each of the Proposed Directors reimbursing the Company in cash for the employee national insurance and PAYE taxes due in respect of those fees. Thereafter, fees will be paid in cash, monthly in arrears.

In the event that the appointment of a Proposed Director terminates for any reason within the first or second year of service, the relevant Proposed Director will reimburse the Company in cash for the value of any over-payment for that year calculated on a pro-rata basis.

The appointment of each Proposed Director is for an initial term of two years and can be terminated by either party upon three months' notice (although the Proposed Directors cannot give notice to terminate their appointment prior to the end of any twelve-month period during which they have been remunerated annually in advance in shares) or immediately by the Company in certain circumstances.

In the event that a third-party takes direct or indirect beneficial ownership of more than 50 per cent. of the share capital, voting rights or assets of the Company or of another participating interest carrying the right to direct the affairs of the Company (a "Change of Control") for a consideration per Ordinary Share which is at least a 100 per cent. premium to the Placing Price, the annual fees of the Proposed Directors for the second year's service (to the extent that any amount has not already been paid) will become payable by the Company in cash as soon as the transaction leading to the Change of Control becomes unconditional and any reimbursement obligation of advance payment shall not apply in the event of termination after the Change of Control. This payment will be satisfied by the issuance to the Proposed Directors of Director Fees Shares.

Corporate governance

The Executive Directors and the Proposed Directors recognise the importance of good governance arrangements. Following the changes detailed above, the Company intends to initiate a process to identify and appoint a second independent Non-Executive Director in addition to Nigel Burton, who is deemed independent, with a view to making an appointment as soon as reasonably practicable and ideally within six months following Admission, subject to finding an appropriate candidate with relevant experience. Further consideration will be given to appointing a third independent Non-Executive Director following the anniversary of completion of the Transaction and before the Company's 2022 annual general meeting.

11. PROPOSED WARRANTS FOR DIRECTORS

To incentivise the Executive Directors and the Proposed Directors appropriately, the following Director Warrants, issued pursuant to the Director Warrant Instrument, will be awarded subject to Admission.

Director

Number of Ordinary Sharessubject to Director Warrants

Number of Ordinary Sharessubject to Broker Warrants

Number of Ordinary Sharessubject to Promoter Warrants

Mark Slade

30,000,000

10,000,000

-

David Rae

30,000,000

6,250,000

-

Simon Wilkinson

30,000,000

-

500,000,000

Dr Nigel Burton

30,000,000

25,000,000

-

TOTAL

120,000,000

41,250,000

500,000,000

 

The Director Warrants, which are non-transferable, are separate from the Broker Warrants and the Promoter Warrants and will be exercisable at the Placing Price for five years from Admission, provided that the Ordinary Shares have traded at a Volume Weighted Average Price (VWAP) at or above a 50 per cent. premium to the Placing Price for 20 consecutive Business Days, or on a change of control of the Company.

The grant of the Promoter Warrants, which are not part of the incentivisation scheme but included in the above table for completeness, are conditional upon each of the Resolutions being passed at the forthcoming General Meeting and allocated based on the Proposed Director's participation in the Placing.

The Broker Warrants included above are an agreed allocation of the Broker Warrants granted to JIM Nominees Limited (as nominee on behalf of Turner Pope), further details of which are set out in paragraph 5 above. These are not part of the incentivisation scheme but included in the above table for completeness. The issue of the Broker Warrants is conditional upon each of the Resolutions being passed at the forthcoming General Meeting and the Broker Warrants will be allocated to the Executive Directors and Proposed Directors based on their participation in the Placing and the Subscription.

In aggregate, the 661,250,000 Ordinary Shares subject to the Promoter Warrants, Director Warrants and Broker Warrants granted to the Executive Directors and the Proposed Directors represent 26.3 per cent. of the Enlarged Issued Share Capital (i.e. after the issue of the Placing Shares, the Subscription Shares and the Fees Shares (excluding 42,500,000 Fees Shares in respect of the second year's fees of the Proposed Directors)). This figure reduces to 14.2 per cent. of the aggregate of the Enlarged Issued Share Capital as further increased by the exercise in full of the Broker Option, the Promoter Warrants, the Cornerstone Investor Warrants, the Broker Warrants, and the Director Warrants (and assuming no other issuance, including such as that which may arise from the exercise of other options which may be granted to other employees in future).

12. GENERAL MEETING

The General Meeting has been convened for 10.00 a.m. on 21 May 2021 and will be held at the offices of Turner Pope at 8 Frederick's Place, London, EC2R 8AB. The Company's preference would be to welcome Shareholders in person to the General Meeting. However, at present, as a result of the COVID-19 pandemic, there continue to be restrictions on gatherings of people indoors.

The Company will therefore arrange to hold the General Meeting as a closed meeting, with the minimum attendance required to form a quorum under the Company's articles of association. These Shareholders will each be directors, officers or employees of the Company. Shareholders will not be permitted to attend the General Meeting in person but can be represented by the Chairman of the General Meeting acting as their proxy.

Given the constantly evolving nature of the situation, should circumstances change before the time of the General Meeting, the Company intends to ensure that it is able to adapt arrangements and to welcome Shareholders to the General Meeting, within safety constraints and in accordance with government guidelines. Should it become possible to do so, the General Meeting will be open for all Shareholders to attend. Any changes to the running of the General Meeting will be notified via a Regulatory Information Services as early as is possible before the date of the General Meeting. Any updates to the position will also be included on the Company's website at www.locationsciencesgroup.ai.

 

 

EXPECTED TIMETABLE OF PRINCIPAL EVENTS

Announcement of the Transaction

 4 May 2021

Publication and posting of the Circular and Form of Proxy

4 May 2021

Latest time and date for applications for the Broker Option

8.00 a.m. on 5 May 2021

Announcement of result of Broker Option

6 May 2021

Latest time and date for receipt of Forms of Proxy for the General Meeting

10.00 a.m. on 19 May 2021

Time and date of General Meeting

10.00 a.m. on 21 May 2021

Announcement of result of General Meeting

21 May 2021

Admission and commencement of dealings in New Ordinary Shares

8.00 a.m. on 25 May 2021

CREST accounts credited in respect of New Ordinary Shares in uncertificated form

25 May 2021

Despatch of definitive share certificates in respect of New Ordinary Shares to be issued in certificated form

week commencing 31 May 2021

Notes:

(1) If any of the above times and/or dates change, Shareholders will be notified of the revised times and/or dates by the Company via announcement through a Regulatory Information Service.

(2) All of the above times refer to London time unless otherwise stated.

(3) Admission and dealings in the New Ordinary Shares are conditional upon, inter alia, the passing of the Resolutions at the General Meeting.

 

 

KEY STATISTICS

Placing statistics

Number of Existing Ordinary Shares

587,337,398

Nominal value of Existing Ordinary Shares

0.1 pence

Number of Placing Shares

1,737,500,000

Number of Subscription Shares

12,500,000

Number of Fees Shares*

180,500,000

Enlarged issued share capital following the issue of the Placing Shares, the Subscription Shares and the Fees Shares*

2,517,837,398

Placing Shares, Subscription Shares and Fees Shares* as a percentage of the enlarged issued share capital

76.7 per cent.

Placing Price of Ordinary Shares to be issued as Placing Shares

0.2 pence

Market capitalisation (at the Placing Price) following the issue of the Placing Shares, the Subscription Shares and the Fees Shares*

£5,035,675

Expected gross proceeds of the Placing and Subscription

£3,500,000

Note: These placing statistics assume that no further Ordinary Shares are issued following the date of this announcement apart from the Placing Shares, the Subscription Shares and the Fees Shares*, and that no Broker Option Shares are issued.

 

* Excluding 42,500,000 Fees Shares in respect of the second year's fees of the Proposed Directors.

 

Broker Option statistics

Maximum number of Broker Option Shares

175,000,000

Maximum additional gross proceeds from the full exercise of the Broker Option

£350,000

Potential enlarged issued share capital on Admission following the issue of the Placing Shares, the Subscription Shares, the Fees Shares* and the Broker Option Shares if fully subscribed

2,692,837,398

Placing Shares, Subscription Shares, Fees Shares* and Broker Option Shares as a percentage of the potential enlarged issued share capital on Admission

78.2 per cent.

Note: These Broker Option statistics assume that no further Ordinary Shares or New Ordinary Shares are issued following the date of this announcement apart from the Placing Shares, the Subscription Shares and the Fees Shares*, and the maximum number of Broker Option Shares are issued.

* Excluding 42,500,000 Fees Shares in respect of the second year's fees of the Proposed Directors.

 

Fully Diluted Share Capital statistics

Number of Ordinary Shares over which Promoter Warrants will be issued

1,500,000,000

Number of Ordinary Shares over which Cornerstone Investor Warrants will be issued

250,000,000

Number of Ordinary Shares over which Director Warrants will be issued

120,000,000

Number of Ordinary Shares over which Broker Warrants will be issued

100,000,000

Potential fully diluted share capital assuming that the Promoter Warrants, Cornerstone Investor Warrants, Broker Warrants and Director Warrants are exercised in full

4,705,337,398

Note: These fully diluted share capital statistics assume the Placing Shares, the Subscription Shares and all of the Fees Shares, and the maximum number of Broker Option Shares are issued. They do not take into account existing employee share options, which in practical terms have no likelihood of being exercised, other existing warrants or any new share options which may be issued to employees under the Company's existing share option schemes and authorities or any future such schemes.

 

 

DEFINITIONS

The following definitions apply throughout this announcement unless the context requires otherwise:

"Admission"

the admission of the New Ordinary Shares to trading on AIM becoming effective in accordance with the AIM Rules;

"AIM"

AIM, a market operated by the London Stock Exchange;

"AIM Rules"

the AIM Rules for Companies published by the London Stock Exchange from time to time;

"Allenby Capital"

Allenby Capital Limited (and its affiliates) (registered number 06706681), acting as nominated adviser to the Company;

"Board" or "Directors"

the directors of the Company as at the date of this announcement;

"Broker Option"

the option granted to Turner Pope by the Company in the Placing Agreement to enable the Company to raise additional funds through the issue of the Broker Option Shares at the Placing Price (in addition to the Placing Shares), details of which are set out in paragraph 5 of this announcement;

"Broker Option Shares"

up to 175,000,000 Ordinary Shares in respect of which the Broker Option may be exercised;

"Broker Warrant Instrument"

the warrant instrument granting unlisted warrants over Ordinary Shares to JIM Nominees Limited (as nominee on behalf of Turner Pope) and to be executed by the Company on Admission;

"Broker Warrants"

unlisted warrants to subscribe for up to 100,000,000 Ordinary Shares, to be issued to JIM Nominees Limited (as nominee on behalf of Turner Pope), further details of which can be found in paragraph 5 of this announcement;

"Business Day"

any day on which banks are generally open in England and Wales for the transaction of business, other than a Saturday, Sunday or public holiday;

"certificated" or "in certificated form"

a share or other security not held in uncertificated form (i.e. not in CREST);

"Company"

Location Sciences Group plc (registered number 06458458);

"Concert Party"

together Richard Hughes, Rebecca Hughes, Abigail Hughes, Mahmud Kamani, Samir Kamani, Umar Kamani, Adam Kamani, Petar Cvetkovic, Carol Kane, Daron Lee, John Lyttle, Shaun Mealey, Christian Stephenson and Simon Wilkinson;

"Cornerstone Investors"

Ben Turner and James Pope, the founders of Turner Pope, and their wives, Donna Turner and Maxine Pope, respectively;

"Cornerstone Investor Warrant Instrument"

the warrant instrument granting unlisted warrants over Ordinary Shares to the Cornerstone Investors and to be executed by the Company on Admission;

"Cornerstone Investor Warrants"

unlisted warrants to subscribe for up to 250,000,000 Ordinary Shares to be issued to the Cornerstone Investors, further details of which can be found in paragraph 5 of this announcement;

"CREST"

a relevant system for paperless settlement of trades in securities and the holding of uncertificated securities operated by Euroclear in accordance with the CREST Regulations;

"CREST Regulations"

the Uncertificated Securities Regulations 2001 (SI 2001/3755), including: (i) any enactment or subordinate legislation which amends or supersedes those regulations; and (ii) any applicable rules made under those regulations for the time being in force;

"Director Warrant Instrument"

the warrant instrument granting unlisted warrants over Ordinary Shares to the Directors and the Proposed Directors and to be executed by the Company on Admission;

"Director Warrants"

unlisted warrants to subscribe for up to 120,000,000 Ordinary Shares, to be issued to the Directors and the Proposed Directors, further details of which can be found in paragraph 11 of this announcement;

"Enlarged Issued Share Capital"

the entire issued share capital of the Company immediately following Admission (assuming that the Placing and Subscription is fully subscribed, the Fees Shares (excluding 42,500,000 Fees Shares in respect of the second year's fees of the Proposed Directors) are issued, no Broker Option Shares are issued and assuming that no further Ordinary Shares are issued following the date of this announcement and prior to completion of the Placing and Subscription);

"EIS"

Enterprise Investment Scheme (as such term is used under Part 5 of the Income Tax Act 2007);

"Euroclear"

Euroclear UK & Ireland Limited;

"Executive Directors"

Mark Slade and David Rae;

"Existing Ordinary Shares"

the 587,337,398 Ordinary Shares in issue on the date of this announcement, all of which are admitted to trading on AIM;

"FCA"

the UK Financial Conduct Authority;

"Fees Shares"

223,000,000 Ordinary Shares to be issued in respect of: (i) fees due to Turner Pope for its first year of joint broking services to be provided to the Company; (ii) fees and commission due to Turner Pope pursuant to the Placing; and (iii) the first and second year's fees of the Proposed Directors in accordance with the Proposed Directors' letters of appointment;

"Form of Proxy"

the form of proxy for use by Shareholders in connection with the General Meeting;

"FSMA"

Financial Services and Markets Act 2000 (as amended);

"General Meeting"

the general meeting of the Company convened for 10.00 a.m. on 21 May 2021;

"Independent Directors"

Kelvin Harrison and Benjamin Chilcott;

"Independent Shareholders"

the Shareholders who are independent of the Concert Party;

"London Stock Exchange"

London Stock Exchange plc;

"New Ordinary Shares"

the Placing Shares, the Subscription Shares, the Fees Shares (excluding 42,500,000 Fees Shares in respect of the second year's fees of the Proposed Directors) and the Broker Option Shares (if any);

"Notice"

the notice convening the General Meeting;

"Ordinary Shares"

the existing ordinary shares of 0.1 pence each in the share capital of the Company;

"Panel"

the Panel on Takeovers and Mergers;

"Placees"

subscribers for Placing Shares and/or Broker Option Shares;

"Placing"

the placing of Placing Shares at the Placing Price pursuant to the Placing Agreement to certain institutional and other investors;

"Placing Agent"

Turner Pope;

"Placing Agreement"

the conditional placing agreement dated 4 May 2021 between the Company, Allenby Capital and Turner Pope relating to the Placing and the Broker Option;

"Placing Price"

0.2 pence per Ordinary Share;

"Placing Shares"

1,737,500,000 Ordinary Shares conditionally placed with certain institutional and other investors pursuant to the Placing Agreement;

"Promoter Warrant Instrument"

the warrant instrument granting unlisted warrants over Ordinary Shares to certain members of the Concert Party and to be executed by the Company on Admission;

"Promoter Warrants"

unlisted warrants to subscribe for up to 1,500,000,000 Ordinary Shares to be issued to certain members of the Concert Party, further details of which can be found in paragraph 5 of this announcement;

"Proposed Directors"

Simon Wilkinson and Dr Nigel Burton;

"Registrar"

Computershare Investor Services PLC, The Pavilions, Bridgwater Road, Bristol, BS99 6ZY;

"Regulatory Information Service"

a service approved by the FCA for the distribution to the public of regulatory announcements and included within the list maintained on the FCA's website;

"Resolutions"

the resolutions being put to Shareholders in order to give effect to the Transaction;

"Rule 9 Waiver"

the waiver by the Panel of the obligations which would otherwise arise on the part of any member of the Concert Party (individually or collectively) under Rule 9 of the Takeover Code in connection with the Transaction;

"Shareholders"

holders of Ordinary Shares;

"Subscription"

the subscription for the Subscription Shares by one of the Executive Directors;

"Subscription Shares"

12,500,000 Ordinary Shares conditionally subscribed by one of the Executive Directors pursuant to the Subscription;

"Takeover Code" or "the Code"

the City Code on Takeovers and Mergers, as amended from time to time;

"Transaction"

the Placing, the Subscription, the Broker Option, the grant of the Promoter Warrants, the grant of the Cornerstone Investor Warrants, the grant of the Director Warrants, the grant of the Broker Warrants, the allotment of Fees Shares, the proposed changes to the Board and the Rule 9 Waiver;

"Turner Pope"

Turner Pope Investments (TPI) Ltd (registered number 09506196), acting as placing agent to the Company;

"uncertificated" or "uncertificated form"

recorded on the register of members of the Company as being held in uncertificated form in CREST and title to which, by virtue of the CREST Regulations, may be transferred by means of CREST;

"United Kingdom" or "UK"

the United Kingdom of Great Britain and Northern Ireland;

"VCT"

a venture capital trust under Part 6 of the Income Tax Act 2007; and

"VCT/EIS Shares"

such number of Placing Shares and/or Broker Option Shares to be allotted and issued to certain VCTs or to certain persons seeking to invest in "eligible shares" for the purpose of the EIS.

 

About Location Sciences Group PLC:

 

Location Sciences is the pre-eminent global location verification provider to the $160 billion digital advertising industry. Working in partnership with brands, media agencies and suppliers to reduce ad-wastage and improve the effectiveness of location-based advertising campaigns.

 

The digital advertising market-place remains unregulated and un-monitored, with an estimated $19 billion wasted on ad-fraud in 2018. Location Sciences has developed Verify, the world's first independent location verification product. Utilising sophisticated machine learning and pattern recognition technologies, Verify detects location ad-fraud and shines a light on location data inaccuracy with the aim of bringing back integrity, transparency and trust to the market place.

 

Rule 26 website: www.locationsciencesgroup.ai

Verify website: www.locationsciences.ai

LinkedIn: https://www.linkedin.com/company/locationsciences

Twitter: @LocationSci

 

 

MiFID II

 

Solely for the purposes of the product governance requirements contained within: (a) EU Directive 2014/65/EU on markets in financial instruments, as amended and as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MiFID II"); (b) Articles 9 and 10 of Commission Delegated Directive (EU) 2017/593 supplementing MiFID II as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018; and (c) the Handbook of rules and guidance issued by the FCA (the "FCA Rules") (together, the "Product Governance Requirements"), and disclaiming all and any liability, whether arising in tort, contract or otherwise, which any "manufacturer" (for the purposes of the Product Governance Requirements) may otherwise have with respect thereto, the Placing Shares have been subject to a product approval process, which has determined that such securities are: (i) compatible with an end target market of retail investors and investors who meet the criteria of professional clients and eligible counterparties, each as defined in MiFID II; and (ii) eligible for distribution through all distribution channels as are permitted by MiFID II (the "Target Market Assessment"). Notwithstanding the Target Market Assessment, distributors should note that: the price of the Placing Shares may decline and investors could lose all or part of their investment; the Placing Shares offer no guaranteed income and no capital protection; and an investment in the Placing Shares is compatible only with investors who do not need a guaranteed income or capital protection, who (either alone or in conjunction with an appropriate financial or other adviser) are capable of evaluating the merits and risks of such an investment and who have sufficient resources to be able to bear any losses that may result therefrom. The Target Market Assessment is without prejudice to the requirements of any contractual, legal or regulatory selling restrictions in relation to the Placing. Furthermore, it is noted that, notwithstanding the Target Market Assessment, TPI will only procure investors who meet the criteria of professional clients and eligible counterparties.

 

For the avoidance of doubt, the Target Market Assessment does not constitute: (a) an assessment of suitability or appropriateness for the purposes of MiFID II or the FCA Rules; or (b) a recommendation to any investor or group of investors to invest in, or purchase, or take any other action whatsoever with respect to the Placing Shares.

 

Each distributor is responsible for undertaking its own target market assessment in respect of the Placing Shares and determining appropriate distribution channels.

 

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1.

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

1. Mark Slade

2. David Rae

2.

Reason for the Notification

a)

Position/status

1. Chief Executive Officer

2. Commercial Director and Chief Financial Officer

b)

Initial notification/Amendment

Initial Notification 

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Location Sciences Group PLC

b)

LEI

213800MKYV25HW2IAX70

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument 

Ordinary shares of 0.1 pence each in the share capital of Location Sciences Group PLC. Identification code (ISIN) for Location Sciences Group PLC ordinary shares: GB00BGT36S19.

Identification code

 

b)

Nature of the transaction

Participation in placing/subscription of new ordinary shares 

c)

Price(s) and volume(s)

Price(s)

Volume(s)

 

1. 0.2p

2. 0.2p

 

1. 20,000,000

2. 12,500,000

 

d)

Aggregated information:

·Aggregated volume

·Price

 

N/A

N/A

e)

Date of the transaction

4 May 2021

f)

Place of the transaction

Outside a trading venue

 

1.

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

1. Mark Slade

2. David Rae

2.

Reason for the Notification

a)

Position/status

1. Chief Executive Officer

2. Commercial Director and Chief Financial Officer

b)

Initial notification/Amendment

Initial Notification 

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Location Sciences Group PLC

b)

LEI

213800MKYV25HW2IAX70

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument 

Warrants over ordinary shares of 0.1 pence each in the share capital of Location Sciences Group PLC. Identification code (ISIN) for Location Sciences Group PLC ordinary shares: GB00BGT36S19.

Identification code

 

b)

Nature of the transaction

Grant of warrants

c)

Price(s) and volume(s)

Price(s)

Volume(s)

Exercise price

1. 0.2p

2. 0.2p

 

1. 40,000,000

2. 36,250,000

 

d)

Aggregated information:

·Aggregated volume

·Price

 

N/A

N/A

e)

Date of the transaction

4 May 2021

f)

Place of the transaction

Outside a trading venue

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IOEBIGDUSGGDGBX
Date   Source Headline
16th Feb 202412:30 pmRNSResult of General Meeting
6th Feb 202410:55 amRNSHolding(s) in Company
30th Jan 20248:00 amRNSSchedule One - Location Sciences Group Plc
30th Jan 20247:30 amRNSRestoration - Location Sciences Group PLC
30th Jan 20247:00 amRNSAcquisition and Publication of Admission Document
25th Jan 20247:00 amRNSLoan Facility and Holding in Company
20th Dec 20237:00 amRNSFurther update on proposed acquisition of Sorted
6th Oct 20237:00 amRNSUpdate on proposed acquisition of Sorted
14th Sep 20237:00 amRNSHalf-year Report
28th Jul 20231:22 pmRNSResult of AGM
25th Jul 20237:00 amRNSHolding(s) in Company
28th Jun 20237:30 amRNSSuspension - Location Sciences Group plc
28th Jun 20237:00 amRNSLoan Agreement, Proposed Acquisition & Suspension
26th Jun 20237:00 amRNSAnnual Financial Report
11th Apr 20234:56 pmRNSHolding(s) in Company
31st Mar 202311:50 amRNSHolding(s) in Company
27th Mar 20237:00 amRNSHolding(s) in Company
22nd Mar 20233:47 pmRNSHolding(s) in Company
22nd Mar 20231:40 pmRNSHolding(s) in Company
22nd Mar 20239:05 amRNSSecond Price Monitoring Extn
22nd Mar 20239:00 amRNSPrice Monitoring Extension
15th Mar 20234:35 pmRNSPrice Monitoring Extension
9th Mar 20234:35 pmRNSPrice Monitoring Extension
27th Sep 20227:00 amRNSHalf-year Report
30th Jun 202211:56 amRNSResult of AGM
6th Jun 20227:00 amRNSNotice of Annual General Meeting
1st Jun 20222:12 pmRNSDirector/PDMR Shareholding
1st Jun 20221:25 pmRNSDirector/PDMR Shareholding
1st Jun 20227:00 amRNSBoard and strategic update
5th Apr 202211:05 amRNSSecond Price Monitoring Extn
5th Apr 202211:00 amRNSPrice Monitoring Extension
30th Mar 20227:00 amRNSAnnual Financial Report
1st Feb 20227:00 amRNSFurther re Sale of Insights dashboard
24th Jan 202211:05 amRNSSecond Price Monitoring Extn
24th Jan 202211:01 amRNSPrice Monitoring Extension
22nd Oct 20218:05 amRNSSale of Insights dashboard
27th Sep 202112:09 pmRNSHalf-year Report
21st Jun 20211:27 pmRNSBusiness Review update and proposed Board changes
21st Jun 202111:28 amRNSHolding(s) in Company
18th Jun 202110:55 amRNSResult of AGM
11th Jun 202110:34 amRNSHolding(s) in Company
8th Jun 202111:54 amRNSHolding(s) in Company
1st Jun 20219:06 amRNSSecond Price Monitoring Extn
1st Jun 20219:00 amRNSPrice Monitoring Extension
28th May 20215:00 pmRNSTotal Voting Rights
28th May 20212:11 pmRNSHolding(s) in Company
27th May 20213:33 pmRNSTR-1 Notification of major holdings
25th May 20218:05 amRNSNotice of AGM
25th May 20218:01 amRNSBoard changes and appointment of Joint Broker
21st May 202111:14 amRNSGM Result, Issue of Equity and Total Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.